Gaining on the Pain: Adventrx To Start Phase III in Sickle Cell
The hot-potato history of the drug candidate that carries the strongest hope for sickle-cell disease (SCD) patients goes back more than two decades, but investors hope the buck will stop with Adventrx Pharmaceuticals Inc. – and plenty of bucks lie ahead, should ANX-188 win at last in upcoming Phase III trials.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter